Lpath Inc Cmn A (LPTN) 1.78 $LPTN Why is Lpath (LPTN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lpath Inc Cmn A (LPTN) 1.78 $LPTN

Why is Lpath (LPTN) Stock Skyrocketing Today?
Madeleine Johnson - Zacks Investment Research - Mon Jun 20, 1:53PM CDT
On Monday, shares of lipid-based therapeutics company Lpath Inc. (LPTN) are skyrocketing, up over 58% in afternoon trading after the company announced that it has been awarded a $1.45 million two-year grant by the Defense Medical Research and Development Program (DMRDP).
LPTN: 1.78 (+0.03)

These Four Emerging Companies Deserve a Look
PR Newswire - Mon Jun 20, 10:34AM CDT
DailyStockReporter.com Briefing: LifeClips Inc. (OTC: LCLP) (OTCQB: LCLP) has been gaining a lot of attention over the weekend following several reports from social financial sites like Investors Hub, that the company's newly acquired company, Batterfly Energy, has its Mobeego product already placed in high profile outlets like in the US like the MGM Grand Hotel's "Grand & Co." (http://bit.ly/24ZMEm5)
MCUR: 1.48 (-0.07), LPTN: 1.78 (+0.03), NVCN: 0.48 (-0.01)

Lpath Awarded Department of Defense Grant for Traumatic Brain Injury Pain Study
PR Newswire - Mon Jun 20, 7:02AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has been awarded a $1.45 million two-year grant by the Defense Medical Research and Development Program (DMRDP), an agency of the U.S. Department of Defense (DoD). This grant will support the study of Lpathomab for the treatment of neuropathic pain associated with traumatic brain injury (TBI). Lpath is working with Professor David Yeomans, Ph.D. of Stanford University's Department of Anesthesia on this project and he will serve as co-principal investigator.
LPTN: 1.78 (+0.03)

Lpath Announces 1-for-14 Reverse Stock Split
PR Newswire - Thu Jun 09, 7:02AM CDT
Lpath, Inc. (NASDAQ: LPTN) announced a 1-for-14 reverse split of the company's issued and outstanding common stock, effective as of 5:00 p.m. EDT on June 10, 2016. Beginning at the opening of trading on June 13, 2016, Lpath's common stock will begin trading on a split adjusted basis, and the number of common shares outstanding will be decreased from approximately 33.1 million pre-split to 2.36 million shares post-split.
LPTN: 1.78 (+0.03)

Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics
PR Newswire - Fri May 27, 7:20AM CDT
At present, the Biotech sphere is in a volatile state, but investors playing in this space know that volatility is what makes this industry interesting to consider. Here are this morning's featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA), CTI BioPharma Corp. (NASDAQ: CTIC), Lpath Inc. (NASDAQ: LPTN), and Heat Biologics Inc. (NASDAQ: HTBX). Sign up now and gain access to the technical alerts for these stocks at:
HTBX: 0.66 (unch), SNTA: 0.29 (+0.01), CTIC: 0.37 (+0.02), LPTN: 1.78 (+0.03)

Trending Stocks: Four of Wall Street's Most Active Equities on April 26, 2016
ACCESSWIRE - Tue Apr 26, 11:12AM CDT
MIAMI, FL / ACCESSWIRE / April 26, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. OGXI, LPTN, UPL, and CPLP have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
OGXI: 0.99 (-0.03), UPL: 0.31 (unch), CPLP: 2.92 (+0.05), LPTN: 1.78 (+0.03)

4 Trending Small Cap Stocks That You Need To Watch Today
ACCESSWIRE - Tue Apr 26, 7:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. LPTN, TLOG, HTM and VSTM are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
VSTM: 1.34 (+0.03), HTM: 0.84 (-0.01), LPTN: 1.78 (+0.03), TLOG: 0.34 (+0.01)

Penny Stocks To Watch: Four Top Small Cap Stocks on Monday April 25
ACCESSWIRE - Mon Apr 25, 11:44AM CDT
MIAMI, FL / ACCESSWIRE / April 25, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. TLOG, LPTN, OREX, and BTUUQ have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
OREX: 0.39 (-0.05), LPTN: 1.78 (+0.03), TLOG: 0.34 (+0.01)

Lpath Reports Favorable Results from Phase 1 Study of Lpathomab
PR Newswire - Tue Apr 19, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today completion of its Phase 1 double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, immunogenicity and pharmacokinetics of Lpathomab(TM) in healthy volunteers. Lpathomab was well tolerated at all doses tested, and no serious adverse events or dose limiting toxicities were observed.
LPTN: 1.78 (+0.03)

Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 1.78 (+0.03), OMER: 11.46 (-0.13), ATHX: 2.30 (+0.01), KPTI: 7.31 (+0.20), CUR: 0.28 (-0.01)

Lpath Completes Dosing in the Lpathomab Phase 1 Safety Study
PR Newswire - Mon Feb 01, 7:00AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today completion of dosing in its Phase 1a double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, immunogenicity and pharmacokinetics of Lpathomab(TM) in healthy volunteers. Lpathomab has been well tolerated at all doses tested, and no serious adverse events or dose limiting toxicities have been observed to date.
LPTN: 1.78 (+0.03)

Diabetic Neuropathy Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/hz8k3l/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diabetic Neuropathy Overview - Therapeutics Development - Pipeline Products for Diabetic Neuropathy - Overview - Pipeline Products for Diabetic Neuropathy - Comparative Analysis - Diabetic Neuropathy - Therapeutics under Development by Companies - Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes - Diabetic Neuropathy - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diabetic Neuropathy - Products under Development by Companies - Diabetic Neuropathy - Products under Investigation by Universities/Institutes - Diabetic Neuropathy - Companies Involved in Therapeutics Development - Araim Pharmaceuticals Inc. - Bristol-Myers Squibb Company - Cebix Incorporated - Celgene Corporation - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - NovaLead Pharma Pvt. Ltd. - Nuvo Research Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Reata Pharmaceuticals, Inc. - Relief Therapeutics S.A. - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hz8k3l/diabetic
PFE: 36.12 (unch), VBAY: (), BMY: 75.34 (+0.06), LPTN: 1.78 (+0.03), OMER: 11.46 (-0.13), CUR: 0.28 (-0.01), CELGZ: 1.43 (+0.08)

Kidney Fibrosis - Pipeline Review 2015
M2 - Wed Jan 06, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/gj84k6/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Cellmid Limited - Evotec AG - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GNI Group Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - Lpath, Inc. - MorphoSys AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - SciFluor Life Sciences, LLC For more information visit http://www.researchandmarkets.com/research/gj...y_fibrosis
RPTP: 6.03 (+0.09), GALT: 1.57 (+0.01), ICPT: 152.00 (+0.27), RGLS: 3.50 (unch), ABBV: 64.35 (+0.19), LPTN: 1.78 (+0.03)

Diabetic Retinopathy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/kr3mll/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Diabetic Retinopathy's therapeutic pipeline. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acucela Inc. - Aerpio Therapeutics, Inc. - Angstrom Pharmaceuticals, Inc. - Antisense Therapeutics Limited - BCN Peptides, S.A. - BioDiem Ltd - Biomar Microbial Technologies - Charlesson LLC. - Crinetics Pharmaceuticals, Inc. - Dimerix Bioscience Pty Ltd - Dynamis Therapeutics, Inc. - EyeGene, Inc. - Foresee Pharmaceuticals, LLC - GTx, Inc. - Icon Bioscience, Inc. - IMMD Inc. - Islet Sciences, Inc. - Kowa Company, Ltd. - LegoChem Biosciences, Inc - Lpath, Inc. - Others (20) For more information visit http://www.researchandmarkets.com/research/kr3mll/diabetic
GTXI: 0.59 (unch), LPTN: 1.78 (+0.03)

Lpath to Hold Corporate Update Conference Call and Live Webcast on Tuesday, November 17th
PR Newswire - Mon Nov 16, 7:00AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today that the company will host a conference call and live webcast tomorrow, Tuesday, November 17, 2015 beginning at 5:00 p.m. EST/2:00 p.m. PST to provide a corporate update and review data from the Nexus Phase 2 study that evaluated iSONEP(TM) as a treatment for patients with wet age-related macular degeneration. The data from the Nexus study was recently presented at the American Academy of Ophthalmology (AAO) Annual Meeting Retina Subspecialty Day.
LPTN: 1.78 (+0.03)

Lpath to Present Nexus Phase 2 Study Data in Wet Age-Related Macular Degeneration at the 2015 American Academy of Ophthalmology Annual Meeting Retinal Subspecialty Day
PR Newswire - Thu Nov 05, 7:00AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that data from the Nexus Phase 2 study of iSONEP(TM) will be presented at the upcoming American Academy of Ophthalmology (AAO) Annual Meeting Retina Subspecialty Day in Las Vegas, Nevada on Saturday, November 14 at 12:59 p.m. Pacific Time. Presenting the data in an oral presentation will be Thomas Ciulla, M.D., a Nexus investigator and practicing ophthalmologist and retinal surgeon in Indianapolis, IN.
LPTN: 1.78 (+0.03)

Spinal Cord Injury - Pipeline Review H2 2015
M2 - Fri Oct 02, 5:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/42rsjm/spinal_cord) has announced the addition of the "Spinal Cord Injury - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal cord Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Asubio Pharma Co., Ltd. - Athersys, Inc. - Axerion Therapeutics, Inc. - BioArctic Neuroscience AB - Cortex Pharmaceuticals, Inc. - Faron Pharmaceuticals Oy - FirstString Research, Inc. - Genervon Biopharmaceuticals, LLC - Grupo Ferrer Internacional, S.A. - Hemostemix Ltd - Histocell S.L. - K-Stemcell Co., Ltd. - Kadimastem Ltd. - Kringle Pharma, Inc. - Lipopharma Therapeutics SL - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuronax SAS - Omeros Corporation - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Q Therapeutics, Inc. - Quark Pharmaceuticals, Inc. - Remedy Pharmaceuticals, Inc. - RhinoCyte, Inc. - SanBio, Inc. - Sirnaomics, Inc. - StemCells, Inc. - Stemedica Cell Technologies, Inc. - TissueGene, Inc. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/42...pinal_cord
VRTX: 90.05 (+1.09), ATHX: 2.30 (+0.01), ACOR: 26.01 (-0.20), LPTN: 1.78 (+0.03), OMER: 11.46 (-0.13), CUR: 0.28 (-0.01)

Lpath Appoints Gary Atkinson Interim Chief Executive Officer
PR Newswire - Tue Sep 29, 3:05PM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that Gary Atkinson has been appointed interim chief executive officer of Lpath, effective immediately. Mr. Atkinson will continue to serve as Lpath's chief financial officer.
ISIS: 57.56 (-0.28), LPTN: 1.78 (+0.03)

Lpath Initiates First-in-Human Dosing in Phase 1 Clinical Trial of Lpathomab
PR Newswire - Tue Sep 15, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that the first cohort of six subjects has been dosed in the Phase 1 clinical trial with LpathomabTM. The double-blind, placebo-controlled, single ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Lpathomab in healthy volunteers. The trial also aims to establish a maximum tolerated dose for future clinical studies in patients with neuropathic pain. The trial will include a total of five cohorts at increasing doses.
LPTN: 1.78 (+0.03)

Polypoidal Choroidal Vasculopathy - Global Clinical Trials Review, H2, 2015
M2 - Mon Sep 14, 5:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vv668j/polypoidal) has announced the addition of the "Polypoidal Choroidal Vasculopathy Global Clinical Trials Review, H2, 2015" report to their offering. "Polypoidal Choroidal Vasculopathy Global Clinical Trials Review, H2, 2015" provides an overview of Polypoidal Choroidal Vasculopathy clinical trials scenario. This report provides top line data relating to the clinical trials on Polypoidal Choroidal Vasculopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Top Companies Participating in Polypoidal Choroidal Vasculopathy Therapeutics Clinical Trials - F. Hoffmann-La Roche Ltd. - Bayer AG - Regeneron Pharmaceuticals, Inc. - Novartis AG - Hawaii Pacific Health - Pfizer Inc. - OXiGENE, Inc. - Oraya Therapeutics, Inc. - Ophthotech Corp. - Lpath, Inc. Clinical Trial Overview of Top Institutes / Government - Southeast Retina Center - Asan Medical Center - Federal University of Sao Paulo - Hyogo College Of Medicine - Kagawa University - Kyungpook National University - La Fondation Ophtalmologique Adolphe de Rothschild - Manhattan Eye Ear & Throat Hospital - Medizinische Universitat Wien - Nihon University For more information visit http://www.researchandmarkets.com/research/vv668j/polypoidal
OXGN: 0.70 (-0.03), PFE: 36.12 (unch), OPHT: 55.85 (+0.78), LPTN: 1.78 (+0.03), REGN: 379.17 (+0.82), NVS: 82.39 (+0.26)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 121

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 173

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 210

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 126

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 123

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 175

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 95

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 203

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

dbt Labs Transforms Data Management with MetricFlow Open Source

Updated Category News Views 735

Embracing Open Source with MetricFlow In a groundbreaking move, dbt Labs recently announced its commitment to advancing trustworthy AI by open sourcing MetricFlow. This initiative represents a significant turning point in how organizations manage and utilize data in the era of artificial intelligence. The shift to an Apache 2.0 license not only safeguards the integrity of...

Continue Reading
EssilorLuxottica Achieves Euro 2 Billion Bond Issuance Success

Updated Category News Views 117

EssilorLuxottica's Successful Bond Issuance EssilorLuxottica has reached a noteworthy milestone by successfully issuing a Euro 2 billion bond at an attractive average rate of 2.99%. This strategic financial move highlights the company's strong position in the market and its appeal to investors. Details of the Bond Issuance The bond issuance features tenors of 4.5 years...

Continue Reading
Streamlined Home Selling Solutions Introduced in North Carolina

Updated Category News Views 292

Revolutionizing Home Selling in North Carolina Fair Cash Offers For Homes has recently launched its innovative service, ‘Sell Your House Fast North Carolina,’ designed to facilitate quick and efficient sales for homeowners. With the ever-changing real estate landscape, many individuals find themselves needing to sell their properties under various circumstances,...

Continue Reading
Ipsen Employee Admits to Insider Trading on Cancer Drug Deal

Updated Category News Views 268

Guilty Plea Tied to a Drugmaker’s Takeover Plans An employee at the French pharmaceutical company Ipsen has agreed to plead guilty to insider trading. The case, centered on trading ahead of a proposed acquisition, underscores the stakes around confidentiality in drug development and the pressures that test corporate governance. What Prosecutors Allege Dishant Gupta,...

Continue Reading
Oscar Health Achieves 52-Week Record with $23.45 Stock Price

Updated Category News Views 221

Oscar Health Achieves New Stock Performance Highs In a striking example of market resilience, Oscar Health, Inc. (OSCR) has reached an impressive 52-week high with its stock hitting $23.45. This achievement signifies a remarkable growth phase for the company, which has experienced an incredible one-year change of 288.51%. Investors have shown strong support for Oscar...

Continue Reading